Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) went up to recover about 22.88% since recording its record low price of $0.17. The stock experienced -4.91% slump, arriving at $0.21 on 3/14/2019. During the day, the stock price traveled from $0.21 to $0.225. This company shares are 2080.95% off its target price of $4.58 and the current market capitalization stands at $13.41M. The recent change has given its price a -9.62% deficit over SMA 50 and -90.78% deficit over its 52-week high. The stock witnessed -1.36% declines, -81.96% declines and -82.84% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found GNMX’s volatility during a week at 12.36% and during a month it has been found around 10.18%.Aevi Genomic Medicine, Inc. (GNMX) Top Holders
Institutional investors currently hold around $3 million or 19.1% in GNMX stock. Look at its top three institutional owners: Adage Capital Partners Gp, L.L.C. owns $1.22 million in Aevi Genomic Medicine, Inc., which represents roughly 9.11% of the company’s market cap and approximately 40.7% of the institutional ownership. Similar statistics are true for the second largest owner, Baker Bros. Advisors Lp, which owns 3,950,419 shares of the stock are valued at $877 thousand. The third largest holder is Blackrock Inc., which currently holds $174 thousand worth of this stock and that ownership represents nearly 1.3% of its market capitalization.Aevi Genomic Medicine, Inc. 13F Filings
At the end of December reporting period, 9 institutional holders increased their position in Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) by some 102,078 shares, 19 decreased positions by 482,695 and 19 held positions by 11,735,815. That puts total institutional holdings at 12,320,588 shares, according to SEC filings. The stock grabbed 2 new institutional investments totaling 12,243 shares while 9 institutional investors sold out their entire positions totaling 113,955 shares.Aevi Genomic Medicine, Inc. (GNMX) Analyst Guide
Several analysts have released their opinion on Aevi Genomic Medicine, Inc. (NASDAQ:GNMX), with 0 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2.5 average brokerage recommendation [T1].